207 results
Keyword Gliben Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Ebymect
dapagliflozin propanediol monohydrate, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/11/2015, Revision: 18, Authorised, Last updated: 06/03/2023 -
List item
Human medicine European public assessment report (EPAR): Eucreas
vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 14/11/2007, Revision: 23, Authorised, Last updated: 29/03/2023 -
List item
Human medicine European public assessment report (EPAR): Zomarist
vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 30/11/2008, Revision: 23, Authorised, Last updated: 20/03/2023 -
List item
Human medicine European public assessment report (EPAR): Velmetia
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 16/07/2008, Revision: 35, Authorised, Last updated: 20/02/2023 -
List item
Human medicine European public assessment report (EPAR): Efficib
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/07/2008, Revision: 32, Authorised, Last updated: 31/01/2023 -
List item
Human medicine European public assessment report (EPAR): Vipidia
alogliptin, Diabetes Mellitus, Type 2
Date of authorisation: 18/09/2013, Revision: 9, Authorised, Last updated: 22/12/2022 -
List item
Human medicine European public assessment report (EPAR): Vokanamet
canagliflozin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 23/04/2014, Revision: 20, Authorised, Last updated: 27/02/2023 -
List item
Human medicine European public assessment report (EPAR): Glustin
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 11/10/2000, Revision: 28, Withdrawn, Last updated: 17/10/2022 -
List item
Human medicine European public assessment report (EPAR): Erivedge
vismodegib, Carcinoma, Basal Cell
Date of authorisation: 12/07/2013,
Date of refusal: 26/04/2013, Revision: 15, Authorised, Last updated: 20/03/2023 -
List item
Human medicine European public assessment report (EPAR): Komboglyze
metformin hydrochloride, saxagliptin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 24/11/2011, Revision: 19, Authorised, Last updated: 15/12/2022 -
List item
Human medicine European public assessment report (EPAR): Lynparza (updated)
Olaparib, Ovarian Neoplasms
Date of authorisation: 16/12/2014, Revision: 21, Authorised, Last updated: 04/05/2023 -
List item
Human medicine European public assessment report (EPAR): Alkindi
hydrocortisone, Adrenal Insufficiency
Date of authorisation: 09/02/2018, Revision: 8, Authorised, Last updated: 20/03/2023 -
List item
Human medicine European public assessment report (EPAR): Adenuric
febuxostat, Gout
Date of authorisation: 21/04/2008, Revision: 23, Authorised, Last updated: 20/04/2023 -
List item
Human medicine European public assessment report (EPAR): Glubrava
metformin hydrochloride, pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 11/12/2007, Revision: 19, Withdrawn, Last updated: 18/10/2022 -
List item
Human medicine European public assessment report (EPAR): Starlix
nateglinide, Diabetes Mellitus, Type 2
Date of authorisation: 03/04/2001, Revision: 15, Withdrawn, Last updated: 28/06/2022type 2 diabetes (metformin, glibenclamide or troglitazone). Other … -
List item
Human medicine European public assessment report (EPAR): Janumet
sitagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 16/07/2008,
Date of refusal: 18/02/2009, Revision: 29, Authorised, Last updated: 18/11/2022 -
List item
Human medicine European public assessment report (EPAR): Qtern
Saxagliptin, dapagliflozin propanediol monohydrate, Diabetes Mellitus, Type 2; Diabetes Mellitus; Nutritional and Metabolic Diseases; Metabolic Diseases; Glucose Metabolism Disorders
Date of authorisation: 15/07/2016, Revision: 10, Authorised, Last updated: 15/12/2022 -
List item
Human medicine European public assessment report (EPAR): Incresync
alogliptin, pioglitazone, Diabetes Mellitus, Type 2
Date of authorisation: 19/09/2013, Revision: 13, Authorised, Last updated: 09/09/2022 -
List item
Human medicine European public assessment report (EPAR): Icandra (previously Vildagliptin / metformin hydrochloride Novartis)
vildagliptin, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 30/11/2008, Revision: 25, Authorised, Last updated: 09/11/2022 -
List item
Human medicine European public assessment report (EPAR): Glidipion (previously Pioglitazone Actavis Group)
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 15/03/2012,
, Revision: 8, Withdrawn, Last updated: 17/10/2022
-
List item
Human medicine European public assessment report (EPAR): Vipdomet
alogliptin benzoate, metformin hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 18/09/2013, Revision: 10, Authorised, Last updated: 09/09/2022 -
List item
Human medicine European public assessment report (EPAR): Actos
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 13/10/2000, Revision: 29, Authorised, Last updated: 24/05/2022 -
List item
Human medicine European public assessment report (EPAR): Pioglitazone Teva Pharma
pioglitazone hydrochloride, Diabetes Mellitus, Type 2
Date of authorisation: 26/03/2012,, Revision: 13, Withdrawn, Last updated: 30/08/2022
-
List item
Human medicine European public assessment report (EPAR): Tandemact
pioglitazone, glimepiride, Diabetes Mellitus, Type 2
Date of authorisation: 08/01/2007, Revision: 20, Authorised, Last updated: 28/02/2022 -
List item
Human medicine European public assessment report (EPAR): Quinsair
levofloxacin, Cystic Fibrosis; Respiratory Tract Infections
Date of authorisation: 25/03/2015,
, Revision: 15, Authorised, Last updated: 22/12/2022